| 產(chǎn)品編號 | bs-1325R |
| 英文名稱 | Rabbit Anti-PDE4D antibody |
| 中文名稱 | 磷酸二酯酶4D抗體 |
| 別 名 | cAMP specific 3',5' cyclic phosphodiesterase 4D; DKFZp686M11213; FLJ97311; cAMP specific 3' 5' cyclic phosphodiesterase 4D; cAMP specific phosphodiesterase 4D; cAMP specific phosphodiesterase PDE4D; cAMP specific phosphodiesterase PDE4D6; cyclic AMP phosphodiesterase; DPDE 3; DPDE3; Dunce like phosphodiesterase E3; HSPDE4D; PDE 43; PDE43; PDE4DN2; Phosphodiesterase 4D cAMP specific (dunce (Drosophila) homolog phosphodiesterase E3); Phosphodiesterase 4D cAMP specific (phosphodiesterase E3 dunce homolog Drosophila); Phosphodiesterase 4D cAMP specific; Phosphodiesterase 4D, cAMP specific (dunce); Phosphodiesterase E3 dunce homolog Drosophila; STRK 1; STRK1. |
| 研究領域 | 細胞生物 神經(jīng)生物學 信號轉導 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Mouse,Rat (predicted: Human,Rabbit,Pig,Cow,Dog,Horse) |
| 產(chǎn)品應用 | WB=1:500-2000,Flow-Cyt=1μg/Test,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 90kDa |
| 細胞定位 | 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PDE4D: 401-550/809 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Cyclic AMP-dependent phosphodiesterase type D (PDE4D) family is comprise of 5 variants (PDE4D1, D2, D3, D4 and D5). One or more PDE4D subtype variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype variants are expressed in varying ratios and their activity is regulated in tandem with GPCRs stimulation. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein protein interactions with cytoskeletal scaffolding proteins. Function: Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. Subunit: Homodimer for the long isoforms. Isoforms with truncated N-termini are monomeric. Isoform 3 is part of a ternary complex containing PRKAR2A, PRKAR2B and AKAP9. Interacts with PDE4DIP. Identified in a complex composed of RYR1, PDE4D, PKA, FKBP1A and protein phosphatase 1 (PP1). Isoform 5, isoform N3 and isoform 12 bind GNB2L1 via their unique N-terminus. Binds ARRB2. Subcellular Location: Cytoplasm. Membrane. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, centrosome. Note=Found in the soluble fraction, associated with membranes, and associated with the cytoskeleton and the centrosome. Tissue Specificity: Widespread; most abundant in skeletal muscle. Isoform 6 is detected in brain. Isoform 8 is detected in brain, placenta, lung and kidney. Isoform 7 is detected in heart and skeletal muscle. Post-translational modifications: Isoform 3 and isoform 7 are activated by phosphorylation (in vitro), but not isoform 6. Isoform N3 and isoform 12 are phosphorylated on Ser-49, Ser-51, Ser-55 and Ser-59. Sumoylation of long isoforms by PIAS4 augments their activation by PKA phosphorylation and represses their inhibition by ERK phosphorylation. DISEASE: Note=Genetic variations in PDE4D might be associated with susceptibility to stroke. PubMed:17006457 states that association with stroke has to be considered with caution. Similarity: Belongs to the cyclic nucleotide phosphodiesterase family. PDE4 subfamily. SWISS: Q08499 Gene ID: 5144 Database links: Entrez Gene: 5144 Human Entrez Gene: 238871 Mouse Omim: 600129 Human SwissProt: Q08499 Human Unigene: 117545 Human Unigene: 95959 Rat 經(jīng)研究發(fā)現(xiàn)磷酸二酯酶(PDE4D）基因可使缺血性卒中的危險性增高,使人患動脈粥樣硬化及中風的風險性增高,有可能是通過影響動脈內(nèi)平滑肌細胞的增生和擴散相關。目前，ＰＤＥ４Ｄ基因的變化機理并不是完全清楚，有待進一步研究 |
| 產(chǎn)品圖片 |
Sample:Brain(Mouse) Lysate at 30 ug
Primary: Anti-PDE4D (bs-1325R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 90 kD
Observed band size: 100 kD
Sample:Brain(Mouse) Lysate at 30 ug
Primary: Anti-PDE4D (bs-1325R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 90 kD
Observed band size: 90kD
Sample:
Cerebrum (Mouse) Lysate at 40 ug
Primary: Anti- PDE4D (bs-1325R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 90kD
Observed band size: 90 kD
Blank control: RSC96(blue), the cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with ice-cold 90% methanol for 30 min on ice..
Isotype Control Antibody: Rabbit IgG(orange) ;
Secondary Antibody: Goat anti-rabbit IgG-FITC(white blue),
Dilution: 1:200 in 1 X PBS containing 0.5% BSA ;
Primary Antibody Dilution: 1μg in 100 μgL 1X PBS containing 0.5% BSA(green).
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
